Join us Sept. 14 at the U-M Golf Course for the 2024 Alumni Territory Homecoming Tailgate!

Genetic Testing Key To Safer Chemotherapy

June 14, 2024


Read time:

<5 mins
Chemo 20Stock

Some cancer patients carry a genetic variant called DPYD that can lead to a dangerous, sometimes fatally toxic response to a common chemotherapy drug. And while it’s possible to test for the variants and adjust a patient’s treatment plan accordingly, this is not standard practice for cancer care across the U.S. Daniel Hertz, Pharm.D.Ph.D., an expert in clinical pharmacy and advocate for DPYD testing, issues a call to action for standardized testing in this article from the Institute for Healthcare Policy and Innovation.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.